The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine

Antiviral Therapy

Volumn 10, Issue 2, 2005, Pages 357-361

  Sproat, Michael ^a   Pozniak, Anton L ^a   Peeters, Monika ^b   Winters, Bart ^b   Hoetelmans, Richard ^b   Graham, Neil M ^b   Gazzard, Brian G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; GENETICS; MUTATION; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DIDANOSINE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; TREATMENT OUTCOME;

EID: 22844443471     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT & Montaner JS. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349:1294.
2. Moore RD & Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13:1933-1942.
3. Colonno RJ, Wachtfogel YT, Hertogs K & Larder B. Frequency of stavudine and didanosine resistance among a large number of randomly selected HIV-1 isolates. Antiviral Therapy 2000; 5(Suppl 3):85.
4. Picard V, Angelini E, Maillard A, Race E, Clavel F, Chene G, Ferchal F & Molina JM. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. Journal of Infectious Diseases 2001; 184:781-784.
5. Maguire M, Gartland M, Moore S, Hill A, Tisdale M, Harrigan R & Kleim JP. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/ lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 2000; 14:1195-1201.
6. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emini EA, Isaacs R, Chodakewitz JA & Richman DD. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection: 100 week follow-up. Journal of the American Medical Association 1998; 280:35-41.
7. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Antiretroviral treatment for adult HIV infection in 2002; updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2002; 288:222-235.
8. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C & Wainberg MA. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′- dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents & Chemotherapy 1993; 37:1390-1392.
9. Larder B & Bloor S. Analysis of clinical isolates and site-directed mutants reveals the genetic determinants of ddl resistance. 5th International Drug Resistance & Treatment Strategies Workshop. 4-8 June 2001, Scotsdale, AZ, USA. Abstract 47.
10. D'Aquila RT. Incorporating antiretroviral resistance testing into clinical practice. Medscape HIV/AIDS CME Circle. March 2002.
11. Cohen C, Kessler H, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart A & Graham N. Phenotypic resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA3001). Antiviral Therapy 2000; 5(Suppl 3):67.
12. Melnick D, Rosenthal J, Cameron M, Snyder M, Griffith-Howard S, Hertogs K, Verbiest W, Graham N & Pham S. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients. 7th Conference on Retroviruses & Opportunistic Infections. 30 January-2 February 2000, San Francisco, CA, USA. Abstract 786.
13. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F & Girard PM for the Narval Trial Group. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomised trial (NARVAL, ANRS 088). Antiviral Therapy 2000; 5(Suppl 3):67.
14. Richman DD. Drug resistance and its implications in the management of HIV infection. Antiviral Therapy 1997; 2(Suppl 4):41-58.
15. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, Gu K, Song Q, Manne J, Islam S, Castriota G & Prasad VR. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996; 271:1282-1285.
16. Miller V, Sturmer M, Staszewski S, Groschel B, Hertogs K, de Bethune M-P, Pauwels R, Harrigan PR, Bloor S, Kemp SD & Larder BA. The M184V mutation in HIV-1 reverse transriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998; 12:705-712.
17. Winters MA, Bosch RJ, Albrecht MA & Katzenstein DA; AIDS Clinical Trials Group 364 Study Team. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients. Journal of Infectious Diseases 2003; 188:537-540.
18. Eron J, Bosch RJ, Petch L, Fiscus S & Frank I, for the AACTG 307 Protocol Team. Antiretroviral activity of didanosine in lamivudine-experienced subjects in comparison to activity in subjects who were lamivudine-naive. Antiviral Therapy 2002; 7(Suppl 1):S135.
19. Rusconi S, La Seta Catamancio S, Citterio P, Bulgheroni E, Kurtagic S, Galazzi M, Croce F, Moroni M & Galli M. Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine. Antiviral Therapy 2001; 6:41-46.
20. Molina J, Marcelin AG, Pavie J, Heripret L, Merle de Boever C, David-Ouaknine F, Kirstetter M, Katlama C, Lucht F, Troccaz M, Dujardin I, Leleu G & Calvez V. Didanosine (ddI) in treatment-experienced HIV-infected patients: Results from a randomized double-blind study (AI454-176 Jaguar). 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-17 September 2003, Chicago, IL, USA. Abstract 447.